← Patent-cliff monitor small molecule VIJOICE ALPELISIB
Loss of exclusivity February 2037 latest FDA-listed patent expiry
Company Novartis → See this company's full patent-cliff portfolio Drug detail Brand name VIJOICE Active ingredient ALPELISIB Strength 50MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval April 2022 Marketing status RX
Listed patents Patent Expires Type 12427141 February 2037 use U-4288 11433059 February 2037 use U-4359 8227462 April 2033 substance, product 8476268 September 2029 substance, product
Regulatory exclusivity Code Expires ODE-396 April 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.